Blue Horseshoe Stocks: SGYP, PBR Recaps & More

Synergy Pharmaceutical, Inc. SGYP

We determined that the nature of SGYP’s premarket activity on the heels of a positive PR yesterday warranted inclusion in our morning report, and the result was yet another winning performance in what has thus far been a great week.

SGYP proceeded to trade in a daily range from its early low of 6.05 on up to 7.97, marking an intraday spike of 32% on volume which exceeded the 3-month average by more than 20X.

That momentum is spilling over into premarket trading this morning, and we’re seeing another gap up today. We’re going to be very interested to follow the action as the session kicks off, open to the possibility of another dip-and-rip.


`
Axion Power International, Inc. AXPW

Our coverage of AXPW this week yielded up big opportunities right from the start, and the trend continued early in yesterday’s session. The stock broke hard out of the starting gate and made a 30% run from .165-.214. As you can see on the 1-minute chart snapshot below, there were also a couple of subsequent swings that would follow.

AXPW ended up closing at .18, and has traded slightly higher in the premarket today.


Petroleo Brasiliero SA (Petrobras) PBR – Options

We also want to track back to a report on PBR we published on the morning of June 3rd, wherein we formulated some longer-term options ideas; specifically the 08/21 $10 and $11 Calls. The PBR chart has been ripening nicely of late, and as a result we’ve seen some nice chances for gain with those contracts.

August $10 Calls – Range: .31-.64 – Max Gain: 106%
August $11 Calls – Range: .17-.30 – Max Gain: 76%

As you can plainly see, PBR is working on one heck of a chart setup, so we’ll certainly continue to monitor these calls that have consistently been making higher lows and higher highs along with the stock.


StemCells, Inc. STEM

We want to tag STEM for observation this morning in the wake of an interested premarket PR we’ve noticed. The company has received the green light from Health Canada “to expand its Phase II clinical trial for chronic cervical spinal cord injury”. >> Read PR

The stock is gapping up in premarket trading, and if it can manage to break through its recent swing high at .74 once the session begins, things could get rather interesting.


Extended Watchlist:
AMD, AEZS, PARN, ERN, HERO(Big gap-down, possible rebound)